Study Evaluating Etanercept and Methotrexate in Plaque Psoriasis

Wyeth

Status and phase: Completed; Phase 4

Conditions: Psoriasis; Arthritis, Psoriatic

Treatments: Drug: Methotrexate; Drug: Etanercept

Study type: Interventional

Funder types: Industry

Identifiers

NCT00161655

0881A-101696

Details and patient eligibility

About

The purpose of this study is to evaluate the efficacy to clear or almost clear the plaques in plaque psoriasis patients, treated with the combination etanercept and methotrexate compared to etanercept alone.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Active plaque psoriasis involving >10% body surface area and/or minimal screening PASI score 8.
• Methotrexate >7.5 mg/week for the last 3 months

Exclusion criteria

• Predominantly guttate, erythrodermic or pustular psoriasis
• Other skin conditions than psoriasis

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)